▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | GreenCity | Italian Channel Awards | Italian Project Awards | ...

Toku Obtains CE and UKCA Marks for AI Cardiovascular Risk Assessments Through the Eye

Toku, Inc., a commercial medical device company specializing in AI assessment of retinal images, announced today that it has obtained CE and UKCA Marks for its patented CLAiR technology. This signific...

Business Wire

Toku’s patented AI technology, CLAiR, has obtained CE and UKCA Marks. CLAiR provides fast, accurate, non-invasive cardiovascular disease (CVD) risk assessments using standard retinal images. By enabling assessment at the point of care, CLAiR will make detection of CVD risk more accessible, especially for underserved populations who lack healthcare access. By integrating seamlessly with existing retinal cameras, CLAiR enables widespread access to CVD assessments through eye care clinics, primary care, and pharmacies. This improved access can lead to earlier detection - saving lives and reducing healthcare costs.

SAN DIEGO: Toku, Inc., a commercial medical device company specializing in AI assessment of retinal images, announced today that it has obtained CE and UKCA Marks for its patented CLAiR technology. This significant milestone underscores Toku’s commitment to maintaining the highest standards of quality and safety and allows access to the Europe and United Kingdom markets.

CLAiR provides accurate, affordable, non-invasive evaluation for the risk of cardiovascular disease (CVD) at the point of care using retinal images captured during a routine eye exam.

The retina, located in the back of the eye, is the only part of the vascular system that can be photographed easily and non-invasively. The CLAiR technology integrates readily with existing retinal cameras, to provide real-time CVD risk assessments with accuracy comparable to gold standard cardiovascular risk assessments (which typically require blood tests and can take weeks). The AI-powered CLAiR technology identifies elevated cardiovascular risk by analyzing minute changes in the retina and its vasculature. CLAiR results can be shared with a patient’s primary care physician, who can initiate a comprehensive cardiovascular evaluation to guide prevention.

Retinal imaging is routinely performed in many eye care settings and is increasingly being used in pharmacy and primary care clinics across the UK and EU. CLAiR will enable healthcare providers in various settings to identify elevated cardiovascular risk in adult patients with no known history of cardiovascular disease.

“I believe that a retinal image can be considered the ‘fifth vital’ along with temperature, heart rate, respiration rate, and blood pressure,” says Toku CEO Associate Professor Ehsan Vaghefi. “The CE and UKCA marks allow us to bring CLAiR to patients across multiple geographies. In my vision of the future, a retinal image analysis is an integral part of a comprehensive screening for major diseases such as cardiovascular or kidney disease.”

Professor John Marshall, the holder of the original patents for refractive surgery and Emeritus Professor of Ophthalmology at both University College London & Kings College, London says “The eye is the only organ of the body where we can non-invasively view and image blood vessels. The advent of artificial intelligence has enabled analysis of retinal images to predict the occurrence and time course of numerous diseases of the vascular system, including heart attacks and strokes. Such early risk identification allows timely modification of lifestyle and even earlier treatment to prevent or delay onset. Toku’s CLAiR algorithm is a major breakthrough in the field of cardiovascular diseases and should result in lifesaving interventions and improved quality of life for innumerable individuals throughout the world.”

About Toku, Inc.

Toku, Inc. based in San Diego CA, is a cutting-edge technology company that specializes in converting routine eye exams to comprehensive health screening by developing AI-powered tools. The company’s first commercialized product, BioAge, uses AI to analyze biometric markers in the retina to accurately identify an individual’s biological age. In the United States the CLAiR platform has received Breakthrough Device designation from the FDA. Toku is committed to making its technology widely accessible through major partnerships across the world. Toku’s Series A financing was co-led by National Vision, Inc., one of the largest optical retailers in the United States, and Topcon Healthcare, a leading provider of medical devices and intelligent software solutions for the global eye care community.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

A capital increase for the Italian venture builder FoolFarm

FoolFarm launches €9 million capital increase targeting IPO and unveils new investment committee.

ShopFully goes shopping in Spain (again)

ShopFully, the Italian company leader in Europe in drive-to-store solutions, acquired the Spanish Ofertia.

Sicily is more and more digitally connected

Thanks to EXA Infrastructure investments, more routes provide rapid access to mainland Italy and beyond

Italian startup Audio Innova combines AI and metaverse for art preservation

Audio Innova won the first prize in the "Creative AI" category at WAICF in Cannes

Most read

ServiceNow to Acquire Atrinet NetACE Network Technology to Accelerate…

Mobile World Congress -- ServiceNow (NYSE: NOW), the leading digital workflow company making the world work better for everyone, today announced it has…

Virtual Incision Receives FDA Authorization for the MIRA Surgical System…

Virtual Incision Corporation announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization of the MIRA™ Surgical System (MIRA),…

Lenovo Unveils Trailblazing Products and Solutions Designed to Power AI…

Today at MWC 2024, Lenovo unveiled its latest portfolio of purpose-built AI devices, software, and infrastructure solutions, as well as showcased two…

Salesforce Announces Strong Fourth Quarter Fiscal 2024 Results

Salesforce (NYSE: CRM), the #1 AI CRM, today announced results for its fiscal fourth quarter and full fiscal year 2024 ended January 31, 2024. Fourth…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!